Innovus Pharmaceuticals, Inc. (INNV) insiders have most recently took part in a trading activity. On Nov 23, 2017 Esber Henry Jemil, Director bought 100,000 shares having total worth of $9,000 at the price of $0.09 per share, following the transaction a total of 100,000 shares owned by Esber Henry Jemil.
On Nov 22, 2017 Berholtz Randy, EVP, CORPORATE DEVELOPMENT bought 16,880 shares having total worth of $1,688 at the price of $0.1 per share, following the transaction a total of 16,880 shares owned by Berholtz Randy.
Shares of Innovus Pharmaceuticals, Inc. (INNV) traded down 5.1% on Nov 24, 2017, hitting $0.09. 511,740 shares of the company’s stock traded hands. Innovus Pharmaceuticals, Inc. has a 52 week low of $0.08 and a 52 week high of $0.6. The company’s market cap is $0 million.
Innovus Pharmaceuticals Inc was incorporated as North Horizon, Inc. in 1959 as a Utah corporation and changed its domicile in 2007 to the State of Nevada. The Company is a pharmaceutical company engaged in the commercialization, licensing, and development of prescription and non-prescription pharmaceutical products with unique packaging and presentation. Its products are focused in the respiratory, dermatology and autoimmune therapeutic categories and will be marketed to primary care physicians, pediatricians, dermatologists and rheumatologists. The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018